ArticleJournal of applied clinical medical physics2026
Evaluation of dosimetric impact and plan robustness of MLC motion and setup errors in SRS for multiple brain metastases.
Article in Journal of applied clinical medical physics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHyperArc is an effective technique for treating multiple small brain metastases using high-definition, precise radiation. However, the small size of individual lesions makes treatment vulnerable to inherent inaccuracies from beam-limiting devices such as multi-leaf collimators (MLCs), as well as patient setup errors. These uncertainties must be thoroughly evaluated prior to administering a single-fraction, high-dose HyperArc treatment to ensure optimal clinical outcomes. PURPOSE: To comprehensively evaluate the robustness of HyperArc VMAT plans for multiple brain metastases (MBT) against (i) high-definition MLC leaf positional errors and (ii) patient rotational and translational setup variations. METHODS AND MATERIALS: A retrospective analysis of 34 MBT plans from 30 patients with 123 lesions treated using HyperArc VMAT plans was performed. Prescription doses (21-24 Gy) targeted PTVs (GTV + 1 mm), with each plan addressing 2-7 brain metastases (< 2 cm). D
resultsPer our cohort, D
conclusionsOverall, the target dose and V
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.